Clinical trial
Pazopanib in Treating Patients With Malignant Pleural Mesothelioma
NCT00459862 · National Cancer Institute (NCI), NIH · Completed
Key facts
| NCT number | NCT00459862 |
|---|---|
| Title | Pazopanib in Treating Patients With Malignant Pleural Mesothelioma |
| Official title | Phase II Study of GW786034 in Patients With Malignant Pleural Mesothelioma |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Advanced Malignant Mesothelioma, Localized Malignant Mesothelioma, Recurrent Malignant Mesothelioma |
| Intervention type | Drug, Other |
| Interventions | laboratory biomarker analysis, pazopanib hydrochloride |
| Enrollment | 34 |
| Start date | Mar 1, 2007 |
| Primary completion | Apr 1, 2009 |
| Completion | May 1, 2013 |
| First posted | Apr 13, 2007 |
| Last update posted | Feb 24, 2015 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: